Timing and durability of response to erenumab in patients with chronic migraine
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Timing and durability of response to erenumab in patients with chronic migraine. / Tepper, Stewart J.; Lucas, Sylvia; Ashina, Messoud; Schwedt, Todd J.; Ailani, Jessica; Scanlon, James; Klatt, Jan; Chou, Denise E.; Wang, Andrea; Paiva da Silva Lima, Gabriel.
I: Headache, Bind 61, Nr. 8, 2021, s. 1255-1263.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Timing and durability of response to erenumab in patients with chronic migraine
AU - Tepper, Stewart J.
AU - Lucas, Sylvia
AU - Ashina, Messoud
AU - Schwedt, Todd J.
AU - Ailani, Jessica
AU - Scanlon, James
AU - Klatt, Jan
AU - Chou, Denise E.
AU - Wang, Andrea
AU - Paiva da Silva Lima, Gabriel
N1 - Funding Information: This analysis was funded by Amgen Inc. and Novartis Funding Information: The authors thank Lee Hohaia, PharmD (ICON, North Wales, PA), whose work was funded by Amgen Inc., and Jon Nilsen, PhD (Amgen Inc.) for medical writing assistance in the preparation of this manuscript. Publisher Copyright: © 2021 The Authors. Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC on behalf of American Headache Society.
PY - 2021
Y1 - 2021
N2 - Background: Erenumab is a human anti-calcitonin gene-related peptide receptor monoclonal antibody approved for migraine prevention. We sought to further assess the temporal patterns of response to erenumab in patients with chronic migraine (CM), specifically the onset and sustainability of monthly migraine day (MMD) response. Methods: This is a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled study of erenumab for migraine prevention in patients with CM (≥15 headache days/month, including ≥8 migraine days/month). Onset and sustainability were assessed according to MMD reduction from baseline, with the following response categories: responders (≥50% reduction), partial responders (≥30% and <50%), or nonresponders (<30%). Results: Among the erenumab 140 mg group (n = 187), 54.0% (101/187) achieved a response at any month during the study with a median time to onset of monthly response of 1 month. This improvement was maintained in most patients with continued treatment. An initial response was achieved at Month 1 by 28.3% (53/187) of patients; 69.8% (37/53) of whom maintained a response at Months 2 and 3. Although many patients responded early, some patients required longer treatment to achieve a response; 79.4% (27/34) of initial partial responders and 21.0% (21/100) of initial nonresponders subsequently achieved a response. Similar findings were observed for the erenumab 70mg group (n = 188). Conclusion: A majority of erenumab-treated patients with CM who achieved an initial response at Month 1 sustained this benefit. Many patients responded later with continued treatment. Our data support recommendations to assess outcomes after ≥3 months of preventive treatment with erenumab in CM.
AB - Background: Erenumab is a human anti-calcitonin gene-related peptide receptor monoclonal antibody approved for migraine prevention. We sought to further assess the temporal patterns of response to erenumab in patients with chronic migraine (CM), specifically the onset and sustainability of monthly migraine day (MMD) response. Methods: This is a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled study of erenumab for migraine prevention in patients with CM (≥15 headache days/month, including ≥8 migraine days/month). Onset and sustainability were assessed according to MMD reduction from baseline, with the following response categories: responders (≥50% reduction), partial responders (≥30% and <50%), or nonresponders (<30%). Results: Among the erenumab 140 mg group (n = 187), 54.0% (101/187) achieved a response at any month during the study with a median time to onset of monthly response of 1 month. This improvement was maintained in most patients with continued treatment. An initial response was achieved at Month 1 by 28.3% (53/187) of patients; 69.8% (37/53) of whom maintained a response at Months 2 and 3. Although many patients responded early, some patients required longer treatment to achieve a response; 79.4% (27/34) of initial partial responders and 21.0% (21/100) of initial nonresponders subsequently achieved a response. Similar findings were observed for the erenumab 70mg group (n = 188). Conclusion: A majority of erenumab-treated patients with CM who achieved an initial response at Month 1 sustained this benefit. Many patients responded later with continued treatment. Our data support recommendations to assess outcomes after ≥3 months of preventive treatment with erenumab in CM.
KW - chronic migraine
KW - erenumab
KW - response patterns
U2 - 10.1111/head.14193
DO - 10.1111/head.14193
M3 - Journal article
C2 - 34363708
AN - SCOPUS:85112045384
VL - 61
SP - 1255
EP - 1263
JO - Headache
JF - Headache
SN - 0017-8748
IS - 8
ER -
ID: 302064325